MHRAapproval83% confidence
Clinical trials for medicines: modifying a clinical trial approval
Source: MHRA
Why This Matters
Why this matters: sets a approval precedent in the same sub-indication (immunology) as Tozorakimab achieves primary endpoints in Phase III trials for COPD.
Regulatory Analysis
Guidance on the various types of modifications that can be made to a clinical trial approval.
Supporting Context
- Therapeutic area
- Respiratory · COPD
- Sub-indication
- Immunology
Related signal: Tozorakimab achieves primary endpoints in Phase III trials for COPD